Pasrija Chetan, Parchment Nathaniel, Tran Douglas, Mackowick Kristen, Boulos Francesca, Iacono Aldo, Kim June, Griffith Bartley P, Sanchez Pablo G, Pham Si M, Kon Zachary N
Division of Cardiac Surgery, University of Maryland School of Medicine, Baltimore, Maryland.
Department of Medicine, University of Maryland School of Medicine, Baltimore, MD.
J Card Surg. 2020 Sep;35(9):2177-2184. doi: 10.1111/jocs.14874. Epub 2020 Jul 27.
Considerable growth of individual lung transplant programs remains challenging. We hypothesized that the systematic implementation of modular risk components to a lung transplantation program would allow for expeditious growth without increasing mortality.
All consecutive patients placed on the lung transplantation waitlist were reviewed. Patients were stratified by an 18-month period surrounding the systematic implementation of the modular risk components Era 1 (1/2014-6/2015) and Era 2 (7/2015-12/2016). Modular risk components were separately evaluated for donors, recipients, and perioperative features.
One hundred and thirty-two waitlist patients (Era 1: 48 and Era 2: 84) and 100 transplants (Era 1: 32 and Era 2: 68) were identified. There was a trend toward decreased waitlist mortality (P = .07). In Era 2, the use of ex vivo lung perfusion (P = .05) and donor-recipient over-sizing (P = .005) significantly increased. Moreover, transplantation with a lung allocation score greater than 70 (P = .05), extracorporeal support (P = .06), and desensitization (P = .008) were more common. Transplant rate significantly improved from Era 1 to Era 2 (325 vs 535 transplants per 100 patient years, P = .02). While primary graft dysfunction (PGD) grade 3 at 72 hours (P = .05) was significantly higher in Era 2, 1-year freedom from rejection was similar (86% vs 90%, P = .69) and survival (81% vs 95%, P = .02) was significantly greater in Era 2.
The systematic implementation of a modular risk components to a lung transplantation program can result in a significant increase in center volume. However, measures to mitigate an expected increase in the incidence of PGD must be undertaken to maintain excellent short and midterm outcomes.
各个肺移植项目的显著增长仍然具有挑战性。我们假设,将模块化风险因素系统地应用于肺移植项目能够实现快速增长且不增加死亡率。
对所有连续进入肺移植等待名单的患者进行回顾。根据围绕模块化风险因素系统实施的18个月时期,将患者分为第1阶段(2014年1月 - 2015年6月)和第2阶段(2015年7月 - 2016年12月)。分别对供体、受体和围手术期特征的模块化风险因素进行评估。
确定了132名等待名单患者(第1阶段:48名,第2阶段:84名)和100例移植手术(第1阶段:32例,第2阶段:68例)。等待名单死亡率有下降趋势(P = 0.07)。在第2阶段,体外肺灌注的使用(P = 0.05)和供体 - 受体尺寸不匹配(P = 0.005)显著增加。此外,肺分配评分大于70时进行移植(P = 0.05)、体外支持(P = 0.06)和脱敏治疗(P = 0.008)更为常见。从第1阶段到第2阶段,移植率显著提高(每100患者年325例移植手术对535例移植手术,P = 0.02)。虽然第2阶段72小时时3级原发性移植物功能障碍(PGD)(P = 0.05)显著更高,但第2阶段1年无排斥反应率相似(86%对90%,P = 0.69),且生存率(81%对95%,P = 0.02)在第2阶段显著更高。
将模块化风险因素系统地应用于肺移植项目可使中心手术量显著增加。然而,必须采取措施减轻预期的PGD发生率增加,以维持良好的短期和中期结果。